Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65 USD | +0.05% | +0.09% | +241.03% |
May. 10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
May. 09 | Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+241.03% | 4.46B | |
+9.37% | 114B | |
+11.63% | 104B | |
-13.82% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.33% | 17.89B | |
+7.45% | 14.28B | |
+35.58% | 12.55B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- RBC Initiates Alpine Immune Sciences at Outperform With Speculative Risk, Sets Price Target at $19, Sees Opportunity in Autoimmune Disease Market